Meeting
2023 ASCO Annual Meeting
STK11 alterations as predictive biomarkers of resistance to immune checkpoint inhibitors in multiple cancers with mismatch repair gene alterations.
Authors
Michael Iglesia
Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
Michael Iglesia , Moh'd M. Khushman , Kian-Huat Lim , Brian Andrew Van Tine , Jingxia Liu , Katrina Sophia Pedersen , Xiuli Liu , Nikolaos Trikalinos , Rama Suresh , Olivia Aranha , Patrick Grierson , Benjamin R. Tan , Ramaswamy Govindan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2619)
DOI
10.1200/JCO.2023.41.16_suppl.2619
Abstract #
2619
Poster Bd #
461
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Microsatellite instability (MSI), mismatch repair (MMR), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitor (ICI) effectiveness in real-world patients with metastatic colorectal cancer (mCRC).
First Author: Haley Ellis
Poster
2022 ASCO Annual Meeting
Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).
First Author: Camila Bragança Xavier
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2021 ASCO Annual Meeting
The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.
First Author: Karen Kelly